Author

C. Muench

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

C. Prieto-Garcia· 3 shared C. Schuelein-Voelk· 3 shared M. E. Diefenbacher· 3 shared M. Reissland· 3 shared O. Hartmann· 3 shared I. Dikic· 2 shared K. Klann· 2 shared M. Rosenfeldt· 2 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Prieto-Garcia

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

LUBAC assembles a signaling platform at mitochondria for signal amplification and shuttling of NF-ĸB to the nucleus

Z. Wu, L. A. Berlemann, V. Bader, D. A. Sehr, E. Eilers, A. Covallero, J. Meschede, L. Angersbach, C. Showkat, J. B. Michaelis, C. Muench, B. Rieger, D. Namgaladze, M. G. Herrera, F. C. Fiesel, , K. F. Winklhofer

This study shows that LUBAC assembles at mitochondria to amplify and shuttle NF-κB signals to the nucleus during TNF activation.

bioRxiv · May 27, 2022 · PreprintCell Biology

USP28 enables oncogenic transformation of respiratory cells and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.

C. Prieto-Garcia, O. Hartmann, M. Reissland, F. Braun, S. Bozkurt, C. T. Fuss, C. Schuelein-Voelk, A. Buchberger, M. A. Calzado, M. T. Rosenfeldt, I. Dikic, C. Muench, M. E. Diefenbacher

This study shows USP28 promotes lung cancer by stabilizing oncogenes and its inhibition enhances therapy for EGFR, BRAF, and PI3K mutant tumors.

bioRxiv · Sep 6, 2021Cancer Biology

PTEN mutant NSCLC require ATM to suppress pro-apoptotic signalling and evade radiotherapy

T. Fischer, O. Hartmann, M. Reissland, C. Prieto-Garcia, K. Klann, C. Schuelein-Voelk, B. Polat, E. Gebhard-Hartmann, M. Rosenfeldt, C. Muench, M. Flentje, M. E. Diefenbacher

This study shows PTEN-deficient NSCLC cells rely on ATM to repair radiation damage and resist therapy, and ATM inhibition synergizes with radiation in these models.

bioRxiv · Jul 24, 2021 · PreprintCancer Biology

Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma

I. Heid, S. Karakaya, C. Muench, S. S. Lueong, A. M. Winkelkotte, S. T. Liffers, L. Godfrey, P. F. Cheung, K. Savvatakis, G. J. Topping, F. Englert, L. Kritzner, M. Grashei, T. Kunzke, N. Sun, , J. T. Siveke

This study identifies functional metabolic differences between PDAC subtypes and shows that non-invasive HP-MRS can detect glycolytic tumor metabolism.

bioRxiv · Jul 23, 2021 · PreprintCancer Biology

Inhibition of USP28 overcomes Cisplatin-Resistance of Squamous Tumors by Suppression of the Fanconi Anemia Pathway.

C. Prieto-Garcia, O. Hartmann, M. Reissland, T. Fischer, C. R. Maier, M. Rosenfeldt, C. Schuelein-Voelk, K. Klann, R. Kalb, I. Dikic, C. Muench, M. E. Diefenbacher

This study identifies USP28 inhibition as a strategy to overcome cisplatin resistance in squamous cell carcinomas by suppressing the Fanconi Anemia DNA repair pathway.

bioRxiv · Sep 10, 2020Cancer Biology